PXR has been shown to be activated by pregnenolone 16α-carbonitrile (PCN) and mediated its inhibition of CYP7A1 expression, suggesting that potent PXR agonists may be an effective scheme for treating cholestasis [106,107]. Here, NR1I2 is linked to cholestasis.